FDA clears Viatronix 3D cardiac application

Viatronix, a developer of 3D imaging software, has received FDA’s 510(k) market clearance for its V3D-Cardiac module.

The V3D-Cardiac application combines left ventricle and coronary analysis functions into a single user-friendly module, allowing both functions are analyzed in a single application according to the Stony Brook, N.Y.-based company.

Viatronix said that the V3D-Cardiac module has real-time analysis of cardiac CTC data; integration with PACS workstations; one-click segmentation of the heart; one-click selection and analysis of coronary vessels; multi-phase cardiac function review; computation of ejection fraction; coronary vessel endoluminal fly-through; one-click segmentation of the left ventricle and automatic determination of long axis; and customizable reporting is integrated into the workflow.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.